Your browser doesn't support javascript.
loading
R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Modi, Dipenkumar; Kim, Seongho; Surapaneni, Malini; Ayash, Lois; Alavi, Asif; Ratanatharathorn, Voravit; Deol, Abhinav; Uberti, Joseph P.
Affiliation
  • Modi D; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan. Electronic address: drdipen228@gmail.com.
  • Kim S; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, Michigan.
  • Surapaneni M; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
  • Ayash L; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
  • Alavi A; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
  • Ratanatharathorn V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
  • Deol A; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
  • Uberti JP; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
Biol Blood Marrow Transplant ; 26(4): 683-690, 2020 04.
Article in En | MEDLINE | ID: mdl-31682979
ABSTRACT
Allogeneic stem cell transplant (alloSCT) is considered in diffuse large B cell lymphoma (DLBCL) patients with chemorefractory disease or who have relapsed after autologous SCT. Here we present the first report of alloSCT using the R-BEAM (rituximab, carmustine, etoposide, cytarabine, melphalan) conditioning regimen in DLBCL patients. We retrospectively compared long-term alloSCT outcomes of DLBCL patients who received either R-BEAM (n = 47) or reduced-intensity conditioning (RIC) regimens (n = 23). Seventy patients (median age, 53 years) with DLBCL received alloSCT between January 2005 and December 2017. The median number of pretransplant therapies was 3, and 17 patients (24%) received prior autologous SCT. All received rituximab as a frontline or salvage therapy before alloSCT. The donor was unrelated in 42 patients (60%), and peripheral blood stem cells were commonly used (96%). The 6-month cumulative incidence of grades III to IV acute graft-versus-host disease (GVHD) was 36.2% and 8.7% for R-BEAM and RIC, respectively (P = .03). Median follow-up of surviving patients after R-BEAM and RIC was 3.1 and 5.5 years, respectively. Three-year overall survival (OS) after R-BEAM and RIC was 34.4% and 43.4%, respectively (P = .48). At 3 years, R-BEAM was associated with a similar relapse rate (25.5% versus 26.1%, P = .96), nonrelapse mortality (NRM; 39.7% versus 39.1%, P = .98), and relapse-free survival (RFS; 34.8% versus 34.7%, P = .75) compared with RIC. In multivariable analysis lower Karnofsky performance score was associated with lower OS (hazard ratio, .96; P = .05), whereas chemorefractory disease was associated with a higher relapse risk (hazard ratio, 8.8; P = .04). No difference in OS, relapse, NRM, or RFS was noticed between R-BEAM and RIC. R-BEAM regimen seems to be feasible and results in equivalent rates of long-term OS, relapse, NRM, and RFS compared with RIC. However, a significantly higher rate of severe acute GVHD was noticed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Hematopoietic Stem Cell Transplantation / Graft vs Host Disease Type of study: Observational_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2020 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Hematopoietic Stem Cell Transplantation / Graft vs Host Disease Type of study: Observational_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2020 Type: Article